Atlas Trials

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Clinical trial NCT00343551 · COMPLETED

Trial details

NCT number
NCT00343551
Sponsor
Novartis
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Essential Hypertension
Start date
2006-05-01
Primary completion
2007-01-01
Enrollment
654

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.